Cargando…
Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients...
Autores principales: | Agbarya, Abed, Sarel, Ina, Ziv-Baran, Tomer, Schwartz, Orna, Shechtman, Yelena, Kozlener, Ella, Khoury, Rasha, Sheikh-Ahmad, Mohammad, Saiegh, Leonard, Swaid, Forat, Ahmad, Asala Abu, Janzic, Urska, Brenner, Ronen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594524/ https://www.ncbi.nlm.nih.gov/pubmed/37873772 http://dx.doi.org/10.3390/diseases11040128 |
Ejemplares similares
-
Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs
por: Agbarya, Abed, et al.
Publicado: (2021) -
Multi-Center Real-World Outcomes of Nivolumab Plus Ipilimumab and Chemotherapy in Patients with Metastatic Non-Small-Cell Lung Cancer
por: Shalata, Walid, et al.
Publicado: (2023) -
Factors Predicting Type I Gastric Neuroendocrine Neoplasia Recurrence: A Single-Center Study
por: Sheikh-Ahmad, Mohammad, et al.
Publicado: (2023) -
Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
por: Janzic, Urska, et al.
Publicado: (2023) -
Treatment of Rare Mutations in Patients with Lung Cancer
por: Taha, Tarek, et al.
Publicado: (2021)